ONGLYZA® (saxagliptin)

How do you choose the right DPP-4 inhibitor for your patients with type 2 diabetes?

Onglyza: Outcomes beyond glycaemic control

Outcomes beyond glycaemic control
Outcomes beyond glycaemic control

*p=non-inferiority1

1. Scirica BM et al. N Engl J Med 2013; 369: 1317-1326.
2. Ott C et al. Cardiovascular Diabetology 2014; 13: 19.
3. ONGLYZA® Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/22315 (Last accessed August 2017).